Stock 002675 YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Stock

Equities

002675

CNE100001DP5

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-10 pm EDT 		5-day change 1st Jan Change
13.62 CNY -1.80% Intraday chart for Yantai Dongcheng Pharmaceutical Group Co.,Ltd. -1.30% -25.70%
May. 27 Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug MT
May. 20 Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023 CI

Financials

Sales 2024 * 3.36B 463M Sales 2025 * 3.83B 529M Capitalization 11.44B 1.58B
Net income 2024 * 300M 41.35M Net income 2025 * 434M 59.82M EV / Sales 2024 * 3.41 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.98 x
P/E ratio 2024 *
37.6 x
P/E ratio 2025 *
25.9 x
Employees 2,333
Yield 2024 *
1.1%
Yield 2025 *
0.81%
Free-Float 63.12%
More Fundamentals * Assessed data

Chart Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Dynamic Chart

Latest news about Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Dongcheng Biochemicals' Unit Gets Nod to Trial Pancreatic Cancer Drug MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Approves the Cash Dividend for the Year 2023 CI
US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection MT
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug MT
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yantai Dongcheng Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug in Singapore MT
Dongcheng Pharmaceutical to Buy Liver Drug Rights from Affiliate for 85 Million Yuan MT
Dongcheng Pharmaceutical Unit to Buy Rights to Tumor-Detecting Drug for 63 Million Yuan; Shares Up 10% MT
Dongcheng Pharma's Singaporean Unit Gets FDA's Nod to Carry Out Trial on 68GaLNC1007 Injection MT
Yantai Dongcheng Pharma Unit Secures License for Radioactive Cargo Transport MT
Dongcheng Pharmaceutical Gets Nod to Trial Tumor Drug in China MT
Yantai Dongcheng Pharmaceutical's Unit Ties Up With Chinese Physics Institute for Electron Accelerator Development MT
Yantai Dongcheng Pharma Gets Nod to Trial Prostate Cancer Treatment in China MT
Dongcheng Pharma Forms Medical Isotopes JV With Germany’s Eckert & Ziegler MT
More news

Quotes and Performance

1 day-1.80%
1 week-1.30%
Current month-7.03%
1 month+1.19%
3 months-5.29%
6 months-22.35%
Current year-25.70%
More quotes

Highs and lows

1 week
13.02
Extreme 13.02
14.78
1 month
12.68
Extreme 12.68
15.11
Current year
12.05
Extreme 12.05
19.08
1 year
12.05
Extreme 12.05
20.15
3 years
9.94
Extreme 9.94
22.90
5 years
9.94
Extreme 9.94
29.60
10 years
5.50
Extreme 5.5
29.60
More quotes

Managers and Directors - Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Managers TitleAgeSince
Zhi Gang Luo CEO
 Chief Executive Officer 53 18-08-09
Qing Lin Liu CHM
 Chairman 53 98-12-30
Chun Ping Zhu DFI
 Director of Finance/CFO 59 98-12-30
Members of the board TitleAgeSince
Shou Yi You CHM
 Chairman 63 07-12-18
Xiao Jie Liu BRD
 Director/Board Member 42 18-01-22
Chun Xiang Lue PRN
 Corporate Officer/Principal 49 98-12-30
More insiders

ETFs positioned on Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Name Weight AuM 1st Jan change Investor Rating
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 114 M€ +3.73% -
More ETFs positioned on Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Quotes

Date Price Change Volume
24-06-10 13.62 -1.80% 24 304 440
24-06-07 13.87 -0.07% 16,146,600
24-06-06 13.88 -3.61% 18,908,500
24-06-05 14.4 -0.35% 19,009,840
24-06-04 14.45 +4.71% 24,840,950

End-of-day quote Shenzhen S.E., June 10, 2024

More quotes

Company Profile

Yantai Dongcheng Biochemicals Co., Ltd is a China-based company principally engaged in the research, development, manufacture and sales of medical drugs. The Company’s main products are categorized into active pharmaceutical ingredients (APIs), nuclear medicines, chemical drugs and traditional Chinese medicines, which include heparin sodium APIs, chondroitin sulfate, preparation products, radionuclide drugs and others. The Company distributes its products in domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
13.62 CNY
Average target price
17.8 CNY
Spread / Average Target
+30.69%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
YANTAI DONGCHENG PHARMACEUTICAL GROUP CO.,LTD. Stock Yantai Dongcheng Pharmaceutical Group Co.,Ltd.
-25.70% 1.58B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.08% 43.46B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+24.43% 22.61B
SANDOZ GROUP AG Stock Sandoz Group AG
+16.48% 15.15B
CIPLA LIMITED Stock Cipla Limited
+22.78% 14.83B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+57.41% 13.08B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-12.44% 6.72B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+12.71% 5.45B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002675 Stock